

OM protein - protein search, using sw model
 Run on: April 16, 2003, 12:10:40 ; Search time 35 Seconds
 (without alignments)
 440.467 Million cell updates/sec
 Copyright (c) 1993 - 2003 Compugen Ltd.

SUMMARIES

11	456	70.8	119	59.9	21	AYV2457
12	396	59.9	119	21	AYV2458	
13	386	59.9	119	21	AYV2455	
14	358	55.6	69	20	AYV11732	
15	342	53.1	97	21	AYV2456	
16	296	46.0	64	19	AYW33938	
17	225	34.9	48	20	AYV11731	
18	78.5	12.2	191	22	AYU65308	
19	73.3	11.4	70	10	AYU91998	
20	73.5	11.4	70	14	AYR3657	
21	71.5	11.1	108	23	AAQ121337	
22	71	11.0	330	21	ABG52331	
23	71	11.0	1798	19	AAW#0896	
24	71	11.0	3190	22	ABR84634	
25	71	11.0	3275	22	AAU#3095	
26	70.5	10.9	145	23	ABU#3095	
27	70	10.9	117	23	ABG61841	
28	70	10.9	121	20	AYY#61659	
29	70	10.9	121	21	ABE56893	
30	70	10.9	167	20	AYV#08283	
31	70	10.9	167	21	ABU#4082	
32	70	10.9	188	17	ABW#4822	
33	70	10.9	188	17	AAW#0726	
34	70	10.9	188	20	AYY#3442	
35	70	10.9	188	20	AAW#0493	
36	70	10.9	188	21	ABU#6474	
37	70	10.9	188	21	ABU#4083	
38	70	10.9	188	22	AAU#8440	
39	70	10.9	188	22	ABG77791	
40	70	10.9	188	23	ABB#7952	
41	70	10.9	188	23	AAU#3407	
42	70	10.9	188	23	AAE#09217	
43	70	10.9	216	23	ABP#1889	
44	70	10.9	491	22	ABR#9889	
45	70	10.9	543	22	ABB#71263	

No. 13 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Human secreted protein encoded by DNA clone vq8.1. Secreted protein; human; autoimmune disorder; multi-systemic lupus erythematosus; rheumatoid arthritis; haematoopoiesis regulation; tissue regrowth; wound; Alzheimer's disease; Parkinson's disease; Shy-drag cone contraceptive; infection; growth inhibition; hyperpsoriasis.

<p>470</p> <p>Description</p> <hr/> <p>Human secreted protein Human TGC-440 secreted Human signal peptidase Membrane-bound protein Human pro polypeptide Amino acid sequence Human Pro842 (Human Pro842 (UNQ414) Mature human TGC-440 Polypeptide encoded by</p>	<p>seconds (nts) cell updates/sec</p> <p>QLRSFALPL 119</p> <p>1980.DAT:*</p> <p>1981.DAT:*</p> <p>1982.DAT:*</p> <p>1983.DAT:*</p> <p>1984.DAT:*</p> <p>1985.DAT:*</p> <p>1986.DAT:*</p> <p>1987.DAT:*</p> <p>1988.DAT:*</p> <p>1989.DAT:*</p> <p>1990.DAT:*</p> <p>1991.DAT:*</p> <p>1992.DAT:*</p> <p>1993.DAT:*</p> <p>1994.DAT:*</p> <p>1995.DAT:*</p> <p>1996.DAT:*</p> <p>1997.DAT:*</p> <p>1998.DAT:*</p> <p>1999.DAT:*</p> <p>A2000.DAT:*</p> <p>A2001.DAT:*</p> <p>A2002.DAT:*</p>
--	---

ALIGNMENTS

				AAY6668
KW	asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;		ID	AAY6668 standard; protein: 119 AA.
KW	Parkinson's disease; Huntington's diseases; ovulatory defect;		XX	
XX	muscular dystrophy.		AC	AAY6668;
OS	Homo sapiens.		XX	
XX			XX	
PN	WO200000610-A2.		DE	Membrane-bound protein PROB42.
XX			XX	
PD	06-JAN-2000.		KW	Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
XX			XX	pharmaceutical; receptor immunoadhesin; gene mapping.
PF	25-JUN-1999; 99WO-US14484.		OS	Homo sapiens.
XX			XX	
PR	26-JUN-1998; 98US-0090762.		PR	02-JUN-1998; 98US-0087609.
PR	31-JUL-1998; 98US-0094983.		PR	02-JUN-1998; 98US-0087759.
PR	01-OCT-1998; 98US-0102486.		PR	03-JUN-1998; 98US-0087827.
PR	11-DEC-1998; 98US-0112129.		PR	04-JUN-1998; 98US-0088021.
XX			PR	04-JUN-1998; 98US-0088025.
PA	(INCY-) INCYTE PHARM INC.		PR	04-JUN-1998; 98US-0088028.
XX			PR	04-JUN-1998; 98US-0088029.
PI	Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;		PR	04-JUN-1998; 98US-0088030.
PI	Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;		PR	04-JUN-1998; 98US-0088033.
XX	Bandman O;		PR	04-JUN-1998; 98US-0088167.
PR	WPI; 2000-160673/14.		PR	05-JUN-1998; 98US-0088202.
DR	N-PSDB; AA298202.		PR	05-JUN-1998; 98US-0088212.
XX			PR	05-JUN-1998; 98US-0088217.
PT	New human signal peptide-containing proteins useful in treatment,		PR	05-JUN-1998; 98US-0088655.
PT	prevention and diagnosis of e.g. cancer, inflammation and		PR	10-JUN-1998; 98US-0088722.
PT	cardiovascular disease		PR	10-JUN-1998; 98US-0088730.
XX			PR	10-JUN-1998; 98US-00888734.
PS	Claim 1; Page 220-221; 327PP; English.		PR	10-JUN-1998; 98US-00888738.
XX			PR	10-JUN-1998; 98US-00888740.
CC	AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the		PR	10-JUN-1998; 98US-00888741.
CC	human signal peptide-containing Proteins HSPP-1 to HSPP-134. HSPPs have		PR	10-JUN-1998; 98US-00888742.
CC	anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,		PR	10-JUN-1998; 98US-00888810.
CC	neuroprotective, cardiovascular and antiasthmatic activities, and can		PR	10-JUN-1998; 98US-00888811.
CC	be used in gene therapy. HSPPs can be used to treat or prevent disorders		PR	10-JUN-1998; 98US-00888863.
CC	associated with decreased activity or function of HSPP. Antagonists of		PR	10-JUN-1998; 98US-00888874.
CC	HSPP are used to treat or prevent disorders associated with increased		PR	10-JUN-1998; 98US-00888876.
CC	activity or function of HSPP. Such diseases include cell proliferation		PR	10-JUN-1998; 98US-00888878.
CC	(including cancer), inflammation, cardiovascular, neurological,		PR	10-JUN-1998; 98US-00888880.
CC	reproductive or developmental disorders, (e.g. arteriosclerosis,		PR	10-JUN-1998; 98US-00888882.
CC	cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,		PR	10-JUN-1998; 98US-00888884.
CC	asthma, Crohn's disease, microbial or other infections, congestive or		PR	10-JUN-1998; 98US-00888886.
CC	ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's		PR	10-JUN-1998; 98US-00888888.
CC	diseases, schizophrenia, auditory defects, muscular dystrophy). HSPP		PR	10-JUN-1998; 98US-00888890.
CC	nucleic acids can be used for the recombinant production of HSPP, for		PR	10-JUN-1998; 98US-00888892.
CC	detecting HSPP in standard hybridisation and amplification assays (for		PR	10-JUN-1998; 98US-00888894.
CC	diagnosis and monitoring), in gene therapy, as antisense,		PR	10-JUN-1998; 98US-00888896.
CC	triplex-forming or ribozyme therapeutics, for detecting related sequences		PR	10-JUN-1998; 98US-00888898.
CC	or genetic variations, and for chromosomal mapping. HSPP are also used to		PR	11-JUN-1998; 98US-00888901.
CC	raise specific antibodies (Ab) and to screen for agonists and		PR	11-JUN-1998; 98US-00888863.
CC	antagonists (potential therapeutic agents). Ab are used to diagnose, or		PR	11-JUN-1998; 98US-00888876.
CC	monitor, HSPP-related diseases (in usual immunoassays), as therapeutic		PR	11-JUN-1998; 98US-00888879.
CC	antagonists, in competitive drug screens, and for purification of HSPP		PR	12-JUN-1998; 98US-00889105.
CC	from natural sources.		PR	16-JUN-1998; 98US-00889440.
XX	Sequence 119 AA;		PR	16-JUN-1998; 98US-00889512.
SO			PR	16-JUN-1998; 98US-00889514.
Query	Match 100 %; Score 644; DB 21; Length 119;		PR	17-JUN-1998; 98US-00889532.
Best	Local Similarity 100 %; Pred. No. 1.7e-66; Mismatches 0; Indels 0; Gaps 0;		PR	17-JUN-1998; 98US-00889538.
Matches	119; Conservative		PR	17-JUN-1998; 98US-0089539.
QY	1 MKVLISLSSLPLMLMSMVSSSLNPGVARGHRDRQASRRLWQLQEGCECKDNFLRAP 60		PR	17-JUN-1998; 98US-0089600.
Db	1 MKVLISLSSLPLMLMSMVSSSLNPGVARGHRDRQASRRLWQLQEGCECKDNFLRAP 60		PR	18-JUN-1998; 98US-0089653.
QY	61 RRKFMTVSGLKKQCPDCDHFRGNVKTRHHRPKNHSRACOFLKOCOLRSFALPL 119		PR	18-JUN-1998; 98US-0089801.
Db	61 RRKFMTVSGLKKQCPDCDHFRGNVKTRHHRPKNHSRACOFLKOCOLRSFALPL 119		PR	18-JUN-1998; 98US-0089907.
RESULT	4		PR	18-JUN-1998; 98US-0089908.
			PR	19-JUN-1998; 98US-0089941.
			PR	19-JUN-1998; 98US-0089948.
			PR	19-JUN-1998; 98US-0089952.
			PR	22-JUN-1998; 98US-0090246.
			PR	22-JUN-1998; 98US-0090252.
			PR	22-JUN-1998; 98US-0090254.
			PR	23-JUN-1998; 98US-0090349.

PR 23-JUN-1998; 98US-0090355.
 PR 24-JUN-1998; 98US-009429.
 PR 24-JUN-1998; 98US-0090431.
 PR 24-JUN-1998; 98US-0090435.
 PR 24-JUN-1998; 98US-0090444.
 PR 24-JUN-1998; 98US-0090445.
 PR 24-JUN-1998; 98US-0090461.
 PR 24-JUN-1998; 98US-0090472.
 PR 24-JUN-1998; 98US-0090535.
 PR 24-JUN-1998; 98US-0090538.
 PR 24-JUN-1998; 98US-0090540.
 PR 24-JUN-1998; 98US-0090551.
 PR 25-JUN-1998; 98US-0090675.
 PR 25-JUN-1998; 98US-0090678.
 PR 25-JUN-1998; 98US-0090688.
 PR 25-JUN-1998; 98US-0090690.
 PR 25-JUN-1998; 98US-0090691.
 PR 25-JUN-1998; 98US-0090694.
 PR 25-JUN-1998; 98US-0090695.
 PR 26-JUN-1998; 98US-0090696.
 PR 01-JUL-1998; 98US-0091358.
 PR 01-JUL-1998; 98US-0091360.
 PR 01-JUL-1998; 98US-0091544.
 PR 02-JUL-1998; 98US-0091478.
 PR 02-JUL-1998; 98US-0091486.
 PR 02-JUL-1998; 98US-0091519.
 PR 02-JUL-1998; 98US-0091626.
 PR 02-JUL-1998; 98US-0091628.
 PR 02-JUL-1998; 98US-0091633.
 PR 02-JUL-1998; 98US-0091646.
 PR 02-JUL-1998; 98US-0091673.
 PR 07-JUL-1998; 98US-0091982.
 PR 09-JUL-1998; 98US-0092182.
 PR 10-JUL-1998; 98US-0092472.
 PR 20-JUL-1998; 98US-0093339.
 PR 30-JUL-1998; 98US-0094651.
 PR 04-AUG-1998; 98US-0095282.
 PR 04-AUG-1998; 98US-0095301.
 PR 04-AUG-1998; 98US-0095302.
 PR 04-AUG-1998; 98US-0095318.
 PR 04-AUG-1998; 98US-0095321.
 PR 04-AUG-1998; 98US-0095325.
 PR 10-AUG-1998; 98US-0095916.
 PR 10-AUG-1998; 98US-0095929.
 PR 11-AUG-1998; 98US-0096012.
 PR 11-AUG-1998; 98US-0096143.
 PR 12-AUG-1998; 98US-0096146.
 PR 17-AUG-1998; 98US-0096229.
 PR 17-AUG-1998; 98US-0096757.
 PR 17-AUG-1998; 98US-0096766.
 PR 17-AUG-1998; 98US-0096769.
 PR 17-AUG-1998; 98US-0096773.
 PR 17-AUG-1998; 98US-0096791.
 PR 17-AUG-1998; 98US-0096867.
 PR 17-AUG-1998; 98US-0096891.
 PR 17-AUG-1998; 98US-009694.
 PR 17-AUG-1998; 98US-0096895.
 PR 17-AUG-1998; 98US-0096897.
 PR 18-AUG-1998; 98US-0096449.
 PR 18-AUG-1998; 98US-009650.
 PR 18-AUG-1998; 98US-0096559.
 PR 18-AUG-1998; 98US-0096560.
 PR 18-AUG-1998; 98US-0096594.
 PR 19-AUG-1998; 98US-0096895.
 PR 20-AUG-1998; 98US-0097218.
 PR 24-AUG-1998; 98US-0097661.
 PR 26-AUG-1998; 98US-0091951.
 PR 26-AUG-1998; 98US-0091952.
 PR 26-AUG-1998; 98US-0097954.

PR 26 AUG-1998; 98US-0097955.
 PR 26 AUG-1998; 98US-0097971.
 PR 26 AUG-1998; 98US-0097974.
 PR 26 AUG-1998; 98US-0097978.
 PR 26 AUG-1998; 98US-0097979.
 PR 26 AUG-1998; 98US-0097986.
 PR 31 AUG-1998; 98US-0098525.
 PR 16 SEP-1998; 98US-0100634.
 PR 12 JAN-1999; 98US-0115565.

PA (GENENTECH INC.
 XX PT Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK,
 XX PI Wood WI, Yuan J;
 XX DR N-PSDB; AAZ05001.

XX PT Membrane-bound proteins and related nucleotide sequences -
 XX PS claim 12; Fig 99; 822pp; English.

XX The invention provides membrane-bound PRO polypeptides and
 CC polynucleotides encoding them. The PRO sequences of the invention were
 CC identified based on extracellular domain homology screening. The PRO
 CC sequences have homology with proteins including IGF receptors, TIE
 CC ligands and various enzymes. The membrane-bound proteins and receptor
 CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
 CC immunoadhesins, for instance, can be used as therapeutic agents to block
 CC receptor-ligand interactions. The membrane-bound proteins can also be
 CC employed for screening of potential peptide or small molecule inhibitors
 CC of the relevant receptor-ligand interaction. The PRO encoding sequences
 CC are useful as hybridization probes, in chromosome and gene mapping and in
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
 CC will also be useful for the preparation of PRO polypeptides, especially
 CC by recombinant techniques.

XX Sequence 119 AA:
 SQ

Query Match Best Local Similarity 100.0%; score 644; DB 21; Length 119;
 Matches 119; Conservative 100.0%; Pred. No. 1.7e-66;
 Mismatches 0; Ingels 0; Gaps 0;

QY 1 MVALISSLILIPIMIIMSMSSSLNGVADHRDRGQASRWRQEGGCECKDWFLRAP 60
 Db 1 MVALISSLILIPIMIIMSMSSSLNGVADHRDRGQASRWRQEGGCECKDWFLRAP 60

QY 61 RAKFMTVSGLPRKQCPDHFTRGQVNRKTRHRRHRRPKNSRACOFLQOCQLSFLPL 119
 Db 61 RRKFMIVSGLPRKQCPDHFTRGQVNRKTRHRRHRRPKNSRACOFLQOCQLSFLPL 119

RESULT 5
 AAU2903 ID AAU29093
 XX standard; Protein; 119 AA.
 AC AAU29093;
 XX DT 18-DEC-2001 (first entry)
 XX DE Human PRO polypeptide sequence #70.
 XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
 XX OS Homo sapiens.
 XX PN WO200168848-A2.
 XX PD 20-SEP-2001.

QY 61 RRKFMTVSGLPPKKQCPDCDHFKGNVKTRHQRHRKPNKHSRACQQFLKQCOLRSFALPL 119
 ID AAB87538
 XX 61 RRKFMTVSGLPPKKQCPDCDHFKGNVKTRHQRHRKPNKHSRACQQFLKQCOLRSFALPL 119
 AC AAB87538;
 XX
 DT 15-MAY-2001 (first entry)
 XX DE Human PRO842.
 XX Human; PRO protein; mapping.
 KW Homo sapiens.
 OS XX
 XX WO200116318-A2.
 XX 08-MAR-2001.
 XX PD
 XX PF 24-AUG-2000; 2000WO-US233328.
 XX PR 01-SEP-1999; 99WO-US20111.
 PR 15-SEP-1999; 99WO-US21090.
 PR 07-DEC-1999; 99US-0169495.
 PR 09-DEC-1999; 99US-0170362.
 PR 11-FEB-2000; 2000US-0174481.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 01-MAR-2000; 2000WO-US05061.
 PR 03-MAR-2000; 2000US-017202.
 PR 25-APR-2000; 2000US-019397.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 05-JUN-2000; 2000US-0209832.
 XX (GETH) GENENTECH INC.
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;
 XX WPI; 2001-183260/1B.
 DR N-PSDB; AAF92070.
 XX PT Eighty four nucleic acids encoding PRO polypeptides, useful in
 PT molecular biology, including use as hybridization probes, and in
 PT chromosome and gene mapping.
 XX PS
 XX Claim 12; Fig 26; 278pp; English.
 XX CC The present sequence is a human PRO polypeptide (secreted and
 CC transmembrane). The PRO protein, and PRO agonists, PRO antagonists or
 CC anti-PRO antibodies are useful for preparation of a medicament useful in
 CC the treatment of a condition which is responsive to the PRO protein,
 CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be
 CC employed as molecular weight markers for protein electrophoresis. The PRO
 CC coding sequence has applications in molecular biology, including use as
 CC hybridisation probes, and in chromosome and gene mapping.
 XX SQ Sequence 119 AA;
 Query Match 100.0%; Score 644; DB 22; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66; Indels 0; Gaps 0;
 Matches 119; Conservative 0; Mismatches 0;
 XX PT PRO polynucleotides used to produce polypeptides used to target
 PT bioactive molecules such as toxins, radiolabels or antibodies, to
 PT specific cells, to cause targeted cell death -
 XX PS Claim 12; Fig 99; 935pp; English.
 XX CC The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytotoxic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridisation probes, in

chromosomal and gene mapping, and in the generation of anti-sense RNA and DNA. They may also be used to produce transgenic animals which are used to develop and screen therapeutically useful reagents. The PRO nucleotide and protein sequence can be used for tissue typing and in treating cancer. Anti-PRO antibodies can be used in diagnostic assays used in the isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to AAB65300 represent human PRO polynucleotide and protein sequences in the exemplification of the present invention.

Sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.7e-66; Mismatches 0; Indels 0; Gaps 0; Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Sequence 119 AA;

QY 1 MKVLISLLLPLMLMSWMSLNLPGVARGHRHRQASRRWLQEGQECCKDWLRAP 60
Db 1 MKVLISLLLPLMLMSWMSLNLPGVARGHRHRQASRRWLQEGQECCKDWLRAP 60

QY 61 RRKFMTVSGLKKQPCDHFKGNKKTRHRRPKNHSRACQFLKOCQLRSFALPL 119
Db 61 RRKFMTVSGLKKQPCDHFKGNKKTRHRRPKNHSRACQFLKOCQLRSFALPL 119

RESULT 9
AY82454
ID AAY82454 standard; Protein: 97 AA.
XX
AC AAY82454;
XX
DT 30-JUN-2000 (first entry)
DE Mature human TGC-440 secretory protein SEQ ID NO:7.
XX
KW pulmonary function disorder; hepatic function disorder; infectious disease;
TGC-440; secretory protein; immunological disease; KW
KW respiratory function disorder; antiflammatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.
OS Homo sapiens.
XX
PN WO200014226-A1.
XX
PD 16-MAR-2000.
XX
PP 02-SEP-1999; 99WO-JP04765.
XX
PR 03-SEP-1998; 98JP-0250108.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Itoh Y, Ogi K, Tanaka H, Kitada C;
XX
DR WPI; 2000-256978/22.
XX
DR N-PSDB; AIA08345.
XX
PT Secretory protein "TGC440", antibodies to it and compounds promoting or inhibiting its activity for diagnosis and treatment of diseases of the immune system, lung, kidney, liver and intestinal system - Disclosure; Page 80; 86pp; Japanese.

XX
CC The present sequence represents the mature human secretory protein TGC-440. TGC-440 has antiinflammatory, hepatotropic, immunomodulatory, virucide, hepatotropic, antiasthmatic and antibacterial activities, and can be used in vaccines. TGC-440 and the polynucleotide sequence encoding it can be used to treat, prevent and diagnose immunological, lung, liver, kidney or gastrointestinal disorders and infectious diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia, pulmonary hypertension, and Helicobacter pylori infection. An antibody

CC immunospecific for TGC-440 is also useful in the above treatment and diagnosis, and also for quantifying the amount of TGC-440 in a liquid specimen.

XX
SQ Sequence 97 AA;

Query Match 85.1%; Score 548; DB 21; Length 97;
Best Local Similarity 100.0%; Pred. No. 1.6e-55; Mismatches 0; Indels 0; Gaps 0; Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Sequence 97 AA;

QY 1 SINPGVARGHRDRQASRRWLQEGQECCKDWLRAPRPFMTVSGLKKQPCDHFKG 82
Db 61 NVKKTRHQRHRPKNHSRACQFLKOCQLRSFALPL 97

RESULT 10
AAW83153
ID AAW83153 standard; Protein: 93 AA.
XX
AC AAW83153;
XX
DT 28-JAN-1999 (first entry)
DE Polypeptide encoded by gene 7 clone HJPD164.
XX
KW Secreted protein; gene therapy; protein therapy; diagnosis; treatment; KW central nervous system; CNS; immune system; cancer; trauma; liver; KW reproductive disorder; congenital malformation; degenerative disease; KW inflammatory disease; neoplasia; metabolic disorder; testis; placenta; KW brain; T cell; spleen; lung; heart; rhabdomyosarcoma; endocrine system; KW endocrinopathy; endocrine polyglandular syndrome; endocrinoma; sepsis; KW endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone; KW OS Homo sapiens.
XX
PN WO9845712-R2.
XX
PD 15-OCT-1998.
XX
PP 07-APR-1998; 98WO-US06801.
XX
PR 30-MAY-1997; 97US-0048184.
PR 08-APR-1997; 97US-0042126.
PR 08-APR-1997; 97US-0042127.
PR 08-APR-1997; 97US-0042128.
PR 08-APR-1997; 97US-0042154.
PR 08-APR-1997; 97US-0042825.
PR 30-MAY-1997; 97US-0048168.
PR 30-MAY-1997; 97US-0048070.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PT Feng P, NI J, Rosen CA, Ruben SM, Yu G;
XX
DR WPI; 1998-594496/50.

XX
PT New isolated human genes and secreted polypeptides) they encode useful for the diagnosis and treatment of e.g. cancers, CNS disorders, immune system disorders, inflammatory disease and bacterial infections
XX
PT Disclosure; Page 10; 142pp; English. SEQ ID NO: 53 (P126)

XX
CC This represents a polypeptide encoded by the nucleic acid molecule CC designated Gene 7 from the human cDNA clone HJPD164 (deposited CC as clone ATCC 97955 and ATCC 209074) which encodes a human secreted protein of the invention. The gene is expressed primarily in liver, CC spleen, bone marrow and to a lesser extent in amygdala and is useful as reagents for differential identification of tissues in a biological

The invention relates to an animal control device, particularly a trap, for capturing a sample.

PS Claim 1; Fig 3; 86pp; Japanese

Claim 1; Fig 3; 86PB; Japanese

which are useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. Also pathological conditions can be diagnosed by determining the amount of the new polypeptides in a sample or by determining the presence of mutations in the polynucleotides. Specific uses are based on which tissues they are most highly expressed in, and include developing products for the diagnosis or treatment of central nervous system (CNS) and immune system diseases, reproductive disorders, cancers, congenital malformations, degenerative diseases, trauma, inflammatory disease, neoplasia, metabolic disorders, diseases in testes, placenta, liver, brain and activated T cells, spleen, diseases, lung diseases, heart diseases, rhabdomyosarcoma and disorders of the endocrine system or other endocrinopathies.

osteoclastoma and other bone remodelling disorders, bacterial infections and sepsis. The polypeptides are also useful for identifying their binding partners.

		Best Local Similarity	100.0%	Score	524	DB	19	Length	93	
		Matches	93	Conservative	0	Mismatches	0	Indels	0	Gaps
QY	- 27	GVARGIRDQASRRMQLQEESGQCECKDWFLRAPPKEMTVSLPKQCPDHFKGNYKK	86							
Db	1	GVARGIRDQASRRMQLQEESGQCECKDWFLRAPPKEMTVSLPKQCPDHFKGNYKK	86							
QY	87	TRHQHHRKNNKHSRACQQFLKQCOLRSFALPL	119							
Db	- 61	TRHQHHRKNNKHSRACQQFLKQCOLRSFALPL	93							

MUS SP.
WO20014226-A1.
16-MAR-2000.
02-SEP-1999; 99WO-JP04765.
03-SEP-1998; 98JP-0250108.
(TAKE) TAKEDA CHEM IND LTD.
Itoh Y, Ogi K, Tanaka H, Kitada C;
WPI; 2000-256978/22.
N-PSDB; AKA08349, AKA08350.

Secretory protein TAC440, antibodies to it and compounds promoting or inhibiting its activity for diagnosis and treatment of diseases of the immune system, lung, kidney, liver and intestinal system -

The present sequence represents the mature mouse secretory protein TGC-440. TGC-440 has antiinflammatory, nephrotoxic, immunomodulatory, virucidal, hepatotropi, antiasthmatic and antibacterial activities, and can be used in vaccines. TGC-440 and the polynucleotide sequence

CC encoding it can be used to treat, prevent and diagnose immunological, lung, liver, kidney, or gastrointestinal disorders and infectious diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia, pulmonary hypertension, and Helicobacter pylori infection. An antibody, CC immunospecific for TCC-440 is also useful in the above treatment and diagnosis, and also for quantifying the amount of TCC-440 in a liquid specimen.

SQ sequence 97 AA:

Query Match 59.9%; Score 386; DB 21; Length 97;

Best Local Similarity 71.1%; Pred. No. 8; 3e-31;

Matches 69; Conservative 7; Mismatches 21; Index 0; Gaps 0;

XX 23 SLNPVGVARGHDRDGQASRRNQEGGQCECKDWELRAPRKFMVSGLPLPKQCPDCDFK 82

Db 1 SPNPGVARSHGDQHLPARRNLEGQCECKDWFLQAPKKAATAVLGPPRKQCPDCDHVK 60

OY 83 NVKKTHHORHHRKPNHRSRACQOFLQKQCRSFAPL 119

Db 61 REKKNRHOKHHRKSRSRACQOFLKRCRHLASFALPL 97

RESULT 13

AY82455

ID AY82455 standard; Protein: 119 AA.

XX

AC AY82455;

XX

DT 30-JUN-2000 (first entry)

XX

DE Rat TGC-440 secretory protein SEQ ID NO:2.

XX

KW TGC-440; secretory protein; immunological disease; infectious disease; pulmonary function disorder; hepatic function disorder; nephrotropic; KW gastrointestinal function disorder; antiinflammatory; immunomodulatory; KW viricide; hepatotropic; antiasthmatic; antibacterial; vaccine; hepatitis; nephritis; influenza; asthma; pulmonary hypertension; pneumonia; Helicobacter pylori infection.

KW

XX

OS Rattus sp.

XX

PN w0200014226-A1.

XX

PD 16-MAR-2000.

XX

PF 02-SEP-1999; 99WO-JP04765.

XX

PR 03-SEP-1998;

XX

PA 98JP-025010B.

PA (TAKE) TAKEDA CHEM IND LTD.

XX

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

XX

DR WPI; 2000-255978/22.

XX

N-PSDB; AAAU08346, AAAU08347.

XX

CC Secretory Protein TGC440, antibodies to it and compounds promoting or inhibiting its activity for diagnosis and treatment of diseases of the immune system, lung, kidney, liver and intestinal system

XX

PS Claim 1; Fig 2; 86pp; Japanese.

XX

CC The present sequence represents a rat secretory protein designated TCC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory viricide, hepatotropic, antiasthmatic and antibacterial activities, and can be used in vaccines. TGC-440 and the polynucleotide sequence encoding it can be used to treat, prevent and diagnose immunological, lung, liver, kidney or gastrointestinal disorders and infectious diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia, pulmonary hypertension, and Helicobacter pylori infection. An antibody, CC immunospecific for TCC-440 is also useful in the above treatment and diagnosis, and also for quantifying the amount of TGC-440 in a liquid

CC polypeptide into a membrane, or importing a polypeptide into a cell.
 XX Sequence 69 AA;
 SQ 55 6%; Score 358; DB 20; Length 69;
 Best Local Similarity 100.0%; Pred. No. 9.4e-34; Mismatches 0; Indels 0; Gaps 0;
 Matches 69; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Query Match 1 MKVLISSILLPLPIMMSAVSSSLNPVARGHRQASRRWLOEGQECCKDWFLRAP 60
 QY 1 MKVLISSILLPLPIMMSAVSSSLNPVARGHRQASRRWLOEGQECCKDWFLRAP 60
 Db 1 MKVLISSILLPLPIMMSAVSSSLNPVARGHRQASRRWLOEGQECCKDWFLRAP 60
 QY 61 RRKPMIVSG 69
 61 RRKPMIVSG 69

RESULT 15
 AAY82456
 ID AAY82456 standard; Protein; 97 AA.
 XX
 AC AAY82456;
 XX
 DT 30-JUN-2000 (first entry)
 DE Mature rat TGC-440 secretory protein SEQ ID NO:8.
 XX
 KW TGC-440; secretory protein; immunological disease; infectious disease;
 KW pulmonary function disorder; hepatic function disorder; nephrotropic;
 KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
 KW virucide; hepatotropic; antasthmatic; antibacterial; vaccine;
 KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
 KW pneumonia; Helicobacter pylori infection.
 XX
 OS Rattus sp.
 XX
 PN WO200014226-A1.
 XX
 PD 16-MAR-2000.
 XX
 PF 02-SEP-1999; 99WO-JP04765.
 XX
 PR 03-SEP-1998; 98JP-0250108.
 XX
 PA (TAKE) TAKEDA CHEM IND LTD.
 XX
 PI Itoh Y, Ogi K, Tanaka H, Kitada C;
 XX
 DR WPI: 2000-256978/22.
 DR N-PSDB; RAA08348.
 XX
 PT Secretory protein TGC440, antibodies to it and compounds promoting or
 PT inhibiting its activity for diagnosis and treatment of diseases of the
 PT immune system, lung, kidney, liver and intestinal system -
 XX
 PS Disclosure; Page 81; 86pp; Japanese.

The present sequence represents a mature rat secretory protein designated
 CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,
 CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
 CC encoding it can be used to treat, prevent and diagnose immunological,
 CC lung, liver, kidney or gastrointestinal disorder and infectious
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
 CC immunospecific for TGC-440 is also useful in the above treatment and
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
 CC specimen.
 XX
 SQ Sequence 97 AA;

Query Match 53.1%; Score 342; DB 21; Length 97;
 Best Local Similarity 64.9%; Pred. No. 9.9e-32;

Matches 63; Conservative 8; Mismatches 26; Indels 0; Gaps 0;
 QY 23 SLNPGVARGHRQASRRWLOEGQECCKDWFLRAPRKRMTVSLPKQCPDCDKHVK 82
 Db 1 SPNQEVARHHRQASRRWLOEGQECCKDWFLRAPRKRMTVSLPKQCPDCDKHVK 60
 QY 83 NVKTRHQRHRKPKHSRACQPLKQCOLRSFALPL 119
 Db 61 SEKNNROKHHRKSQPSRVCQFLKRCQASFALPL 97
 Job time : 38 secs
 Search completed: April 16, 2003, 12:15:12